RecruitingPhase 2NCT04886284

Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia (CERT)

Sponsor

Todd C. Lee MD MPH FIDSA

Enrollment

60 participants

Start Date

May 20, 2024

Study Type

INTERVENTIONAL

Conditions

Staphylococcus Aureus Bacteremia Staphylococcus Aureus Endocarditis Staphylococcus Aureus Septicemia Staphylococcal Sepsis

Summary

There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia. No randomized controlled trial has been performed. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ertapenem and a drug called Placebo for people with staphylococcal sepsis, staphylococcus aureus bacteremia, and other related conditions. The study is currently recruiting participants at 6 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.